Patents Examined by Deepak Rao
  • Patent number: 9801951
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 31, 2017
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Patent number: 9796714
    Abstract: Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: October 24, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Stephen D. Meriney, Mary Liang
  • Patent number: 9795613
    Abstract: Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: October 24, 2017
    Assignee: Celgene International II SÀRL
    Inventors: Marcus F. Boehm, Esther Martinborough, Manisha Moorjani, Junko Tamiya, Liming Huang, Adam R. Yeager, Enugurthi Brahmachary, Thomas Fowler, Andrew Novak, Premji Meghani, Michael Knaggs, Daniel Glynn, Mark Mills
  • Patent number: 9795608
    Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 24, 2017
    Assignee: PHARMASCIENCE, INC.
    Inventors: Alain Laurent, Yannick Rose
  • Patent number: 9796701
    Abstract: The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 24, 2017
    Assignee: XUANZHU PHARMA CO., LTD.
    Inventors: Frank Wu, Bo Chen
  • Patent number: 9796688
    Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: October 24, 2017
    Assignee: MannKind Corporation
    Inventors: John J. Stevenson, Destardi Moye-Sherman
  • Patent number: 9790189
    Abstract: The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 17, 2017
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Rolf Bohlmann, Ulf Bömer
  • Patent number: 9782390
    Abstract: The present invention relates to novel ?-lactam compounds, their preparation and use. In particular, this invention relates to novel ?-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: October 10, 2017
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Burkhard Klenke, Irith Wiegand, Guido Schiffer, Heike Broetz-Oesterhelt, Samarendra N. Maiti, Jehangir Khan, Andhe Reddy, Zhixiang Yang, Mostafa Hena, Guofeng Jia, Ou Ligong, Hong Liang, Judy Yip, Chuanjun Gao, Sabiha Tajammul, Rahim Mohammad, Ganguli Biswajeet
  • Patent number: 9782406
    Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: October 10, 2017
    Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co., Ltd.
    Inventors: Zhengying Pan, Xitao Li
  • Patent number: 9783505
    Abstract: Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Patrick Papa, Brian Edwin Cathers, Andrew Antony Calabrese, Brandon Wade Whitefield, Brydon Bennett, Daniel Cashion, Deborah Mortensen, Dehua Huang, Eduardo Torres, Jason Parnes, John Sapienza, Joshua Hansen, Katerina Leftheris, Matthew Correa, Maria Mercedes Delgado, Raj K. Raheja, Sogole Bahmanyar, Sayee Hegde, Stephen Norris, Veronique Plantevin-Krenitsky
  • Patent number: 9776959
    Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 3, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hongyuan Wei, Chongjun Liu, Xuyang Zhao, Xiaojie Xu, Hua Bai, Yuncai Zhang
  • Patent number: 9776998
    Abstract: Provided herein are intermediates and processes useful for facile synthesis of compounds of formula (I): or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Q, P1 and P2 are as defined in this disclosure.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 3, 2017
    Assignee: Plexxikon Inc.
    Inventors: Prabha N. Ibrahim, Jack Lin, Wayne Spevak, Jiazhong Zhang
  • Patent number: 9777028
    Abstract: The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 3, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Bing Shi, Zhuoyi Su, Fang Wang
  • Patent number: 9776985
    Abstract: Provided is a novel process for the preparation of alogliptin.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: October 3, 2017
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Navin Ganesh Bhatt, Samir Naik, Ajay Kumar Sharma, Mahendra Joma Choraghe, Shekhar Bhaskar Bhirud
  • Patent number: 9776974
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: October 3, 2017
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 9777024
    Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 3, 2017
    Assignee: Tetra Discovery Partners, LLC
    Inventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
  • Patent number: 9771361
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 26, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
  • Patent number: 9770026
    Abstract: Disclosed is a substituted pyrimidine compound having a structure as represented by formula PY. See the description for the definition of each substituent in the formula. The compound of the present invention provides broad-spectrum bactericidal, pesticidal, and acaricidal activities, provides great control effects against plant diseases such as cucumber downy mildew, corn rust, wheat powdery mildew, rice blast, and cucumber gray mold, specifically provides improved control effects against cucumber downy mildew, corn rust, wheat powdery mildew, and rice blast, provides great control effects against aphid, carmine spider mite, diamondback moth, and armyworm, and acquires great effects at a minimal dosage. The compound of the present invention also provides characteristics such as a simplified preparation method.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: September 26, 2017
    Assignee: Shenyang Sinochem Agrochemicals R&D Co., Ltd.
    Inventors: Changling Liu, Lizeng Wang, Yuquan Song, Xufeng Sun, Jie Lan, Aiying Guan, Junfeng Wang, Jinbo Zhang, Cong Feng, Minna Zhu, Zhinian Li, Lanhui Ren, Xiuhui Chang, Fan Yang, Qin Sun, Wei Chen, Shaowu Liu, Yinping Zhou, Zhonggang Shan, Baoshan Chai, Bin Wang, Jizhong Zhou
  • Patent number: 9771329
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: September 26, 2017
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 9765002
    Abstract: The present invention relates to a process of a cis/trans isomerization of an unsaturated compound A being selected from the group consisting of unsaturated ketones, unsaturated ketals, unsaturated aldehydes, unsaturated acetals, unsaturated carboxylic acids, esters of an unsaturated carboxylic acid and amides of an unsaturated carboxylic acid using polythiol as cis/trans isomerization catalyst. It has been observed that the isomerization is very efficient and fast.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 19, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: René Tobias Stemmler, Nadine Greiner